Cairo – Mubasher: Sabaa International Company for Pharmaceutical and Chemical Industry has received an initial approval from the Egyptian Drug Authority (EDA) to register a drug product (Favipiravir 200 mg), a potential treatment for coronavirus (COVID-19).

Production is expected to start within three months after the completion of the registration procedures, the company said in a statement to the Egyptian Exchange (EGX) on Monday.

The drug will be manufactured at the company’s factory in the industrial zone in Kafr El-Sheikh.

It is worth mentioning that during the first quarter of 2020, the pharmaceutical company reported net profits of EGP 3.16 million, up from about EGP 724,830 in the year-ago period.

Source: Mubasher

All Rights Reserved - Mubasher Info © 2005 - 2020 Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.